Felson DT, Rabasa Gabriela, Chen Xiaoyang, LaValley Michael, Jafarzadeh SR, Lewis CE, et al. The Association of Diuretics and Proton Pump Inhibitors With Chondrocalcinosis. ACR Open Rheumatology 2021;3(6):390-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207690/
Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther 2014;16(5):458. https://www.ncbi.nlm.nih.gov/pubmed/25315665
Gamon E, Combe B, Barnetche T, Mouterde G. Diagnostic value of ultrasound in calcium pyrophosphate deposition disease: a systematic review and meta-analysis. RMD Open 2015;1(1):e000118. https://www.ncbi.nlm.nih.gov/pubmed/26535143
Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population. Rheumatology (Oxford) 2012;51(11):2070-4. https://pubmed.ncbi.nlm.nih.gov/22886340/
Stack J, McCarthy G. Calcium pyrophosphate deposition (CPPD) disease - Treatment options. Best Pract Res Clin Rheumatol 2021;35(4):101720. https://www.ncbi.nlm.nih.gov/pubmed/34756508
Timms AE, Zhang Y, Russell RG, Brown MA. Genetic studies of disorders of calcium crystal deposition. Rheumatology (Oxford) 2002;41(7):725-9. https://www.ncbi.nlm.nih.gov/pubmed/12096219
Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70(4):563-70. https://www.ncbi.nlm.nih.gov/pubmed/21216817
Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011;70(4):571-5. https://pubmed.ncbi.nlm.nih.gov/21257614/
